Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Shares Outstanding for 10 consecutive years, with $56.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Outstanding rose 3.68% year-over-year to $56.3 million, compared with a TTM value of $56.3 million through Sep 2025, up 3.68%, and an annual FY2024 reading of $54.6 million, up 3.01% over the prior year.
  • Shares Outstanding was $56.3 million for Q3 2025 at Spero Therapeutics, roughly flat from $56.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $56.3 million in Q3 2025 and bottomed at $3.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $41.6 million, with a median of $52.8 million recorded in 2023.
  • The sharpest move saw Shares Outstanding soared 593052.53% in 2021, then tumbled 92.34% in 2022.
  • Year by year, Shares Outstanding stood at $32.4 million in 2021, then surged by 61.93% to $52.5 million in 2022, then rose by 1.04% to $53.0 million in 2023, then grew by 3.01% to $54.6 million in 2024, then grew by 3.15% to $56.3 million in 2025.
  • Business Quant data shows Shares Outstanding for SPRO at $56.3 million in Q3 2025, $56.2 million in Q2 2025, and $55.9 million in Q1 2025.